386 related articles for article (PubMed ID: 34638388)
41. Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy-Focus on FcγRIIB.
Teige I; Mårtensson L; Frendéus BL
Front Immunol; 2019; 10():481. PubMed ID: 30930905
[TBL] [Abstract][Full Text] [Related]
42. FcγRIIB as a key determinant of agonistic antibody efficacy.
White AL; Beers SA; Cragg MS
Curr Top Microbiol Immunol; 2014; 382():355-72. PubMed ID: 25116108
[TBL] [Abstract][Full Text] [Related]
43. Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.
Wingert S; Reusch U; Knackmuss S; Kluge M; Damrat M; Pahl J; Schniegler-Mattox U; Mueller T; Fucek I; Ellwanger K; Tesar M; Haneke T; Koch J; Treder M; Fischer W; Rajkovic E
MAbs; 2021; 13(1):1950264. PubMed ID: 34325617
[TBL] [Abstract][Full Text] [Related]
44. Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia.
Aroldi A; Mauri M; Ramazzotti D; Villa M; Malighetti F; Crippa V; Cocito F; Borella C; Bossi E; Steidl C; Scollo C; Voena C; Chiarle R; Mologni L; Piazza R; Gambacorti-Passerini C
J Cell Mol Med; 2023 Oct; 27(20):3053-3064. PubMed ID: 37654003
[TBL] [Abstract][Full Text] [Related]
45. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
[TBL] [Abstract][Full Text] [Related]
46. The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a.
Peluso MO; Adam A; Armet CM; Zhang L; O'Connor RW; Lee BH; Lake AC; Normant E; Chappel SC; Hill JA; Palombella VJ; Holland PM; Paterson AM
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32345627
[TBL] [Abstract][Full Text] [Related]
47. Targeting Fc Receptor-Mediated Effects and the "Don't Eat Me" Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer.
Tian L; Xu B; Teng KY; Song M; Zhu Z; Chen Y; Wang J; Zhang J; Feng M; Kaur B; Rodriguez L; Caligiuri MA; Yu J
Clin Cancer Res; 2022 Jan; 28(1):201-214. PubMed ID: 34645647
[TBL] [Abstract][Full Text] [Related]
48. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells.
Richards JO; Karki S; Lazar GA; Chen H; Dang W; Desjarlais JR
Mol Cancer Ther; 2008 Aug; 7(8):2517-27. PubMed ID: 18723496
[TBL] [Abstract][Full Text] [Related]
49. Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer.
Li C; Xu X; Wei S; Jiang P; Xue L; Wang J;
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504575
[TBL] [Abstract][Full Text] [Related]
50. The anti-B7-H4 checkpoint synergizes trastuzumab treatment to promote phagocytosis and eradicate breast cancer.
Hu X; Liu Y; Zhang X; Kong D; Kong J; Zhao D; Guo Y; Sun L; Chu L; Liu S; Hou X; Ren F; Zhao Y; Lu C; Zhai D; Yuan X
Neoplasia; 2020 Nov; 22(11):539-553. PubMed ID: 32966956
[TBL] [Abstract][Full Text] [Related]
51. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
52. Engineering nanoparticles boost TNBC therapy by CD24 blockade and mitochondrial dynamics regulation.
Zhao M; Li J; Chen F; Han Y; Chen D; Hu H
J Control Release; 2023 Mar; 355():211-227. PubMed ID: 36736908
[TBL] [Abstract][Full Text] [Related]
53. Differential influence on antibody dependent cellular phagocytosis by different glycoforms on therapeutic Monoclonal antibodies.
Kuhns S; Shu J; Xiang C; Guzman R; Zhang Q; Bretzlaff W; Miscalichi N; Kalenian K; Joubert M
J Biotechnol; 2020 Jun; 317():5-15. PubMed ID: 32361021
[TBL] [Abstract][Full Text] [Related]
54. SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.
Ponce LP; Fenn NC; Moritz N; Krupka C; Kozik JH; Lauber K; Subklewe M; Hopfner KP
Oncotarget; 2017 Feb; 8(7):11284-11301. PubMed ID: 28061465
[TBL] [Abstract][Full Text] [Related]
55. Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB.
Manso T; Kushwaha A; Abdollahi N; Duroux P; Giudicelli V; Kossida S
Front Immunol; 2023; 14():1129323. PubMed ID: 37215135
[TBL] [Abstract][Full Text] [Related]
56. Fc gamma receptor IIb on GM-CSF macrophages controls immune complex mediated inhibition of inflammatory signals.
Santegoets KC; Wenink MH; van den Berg WB; Radstake TR
PLoS One; 2014; 9(10):e110966. PubMed ID: 25340460
[TBL] [Abstract][Full Text] [Related]
57. Anticancer efficacy of monotherapy with antibodies to SIRPα/SIRPβ1 mediated by induction of antitumorigenic macrophages.
Sakamoto M; Murata Y; Tanaka D; Kakuchi Y; Okamoto T; Hazama D; Saito Y; Kotani T; Ohnishi H; Miyasaka M; Fujisawa M; Matozaki T
Proc Natl Acad Sci U S A; 2022 Jan; 119(1):. PubMed ID: 34949714
[TBL] [Abstract][Full Text] [Related]
58. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of FcγR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcγRIIb in human macrophages.
Nagelkerke SQ; Dekkers G; Kustiawan I; van de Bovenkamp FS; Geissler J; Plomp R; Wuhrer M; Vidarsson G; Rispens T; van den Berg TK; Kuijpers TW
Blood; 2014 Dec; 124(25):3709-18. PubMed ID: 25352126
[TBL] [Abstract][Full Text] [Related]
60. The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.
Estupina P; Fontayne A; Barret JM; Kersual N; Dubreuil O; Le Blay M; Pichard A; Jarlier M; Pugnière M; Chauvin M; Chardès T; Pouget JP; Deshayes E; Rossignol A; Abache T; de Romeuf C; Terrier A; Verhaeghe L; Gaucher C; Prost JF; Pèlegrin A; Navarro-Teulon I
Oncotarget; 2017 Jun; 8(23):37061-37079. PubMed ID: 28427157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]